Drug intelligence / Profile preview

J2H-1801

Development stage: Preclinical
Lead developer: J2H Biotech
Modality: Small Molecules
Administration: Oral

Overview

J2H-1801 is a small molecule drug candidate developed by J2H Biotech for the treatment of multiple sclerosis. It is designed as a hybrid new drug to overcome the limitations of current MS treatments such as Tecfidera (dimethyl fumarate), aiming to significantly reduce side effects like gastrointestinal issues and flushing while maintaining equivalent efficacy. As of March 2025, J2H-1801 is in preclinical development. Its primary indication is multiple sclerosis, with therapeutic areas including immune system diseases and nervous system diseases.

Beyond the preview

Go deeper on J2H-1801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on J2H-1801.

Explore the full profile